Jean(Abou Yared)YaredMD
Hematology • Baltimore, MDHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias
Associate Professor of Medicine, Blood and Marrow Transplantation Program, University of Maryland School of Medicine
Dr. Yared is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
22 S Greene St, Room N9E12
Univ. Of Md, Marlene & Stewart Greenebaum Cancer Center
Baltimore, MD 21201Phone+1 410-328-1230Fax+1 410-328-1975- Is this information wrong?
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 2010 - 2013
Greater Baltimore Medical CenterResidency, Internal Medicine, 2007 - 2010
St Joseph's University Medical SchoolClass of 2002
Certifications & Licensure
NH State Medical License 2013 - Present
MD State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Start of enrollment: 2017 Oct 23
Publications & Presentations
PubMed
- Final Outcomes from a Phase 2 Trial of Posoleucel in Allogeneic Hematopoietic Cell Transplant Recipients.Michael Schuster, Gary Douglas Myers, Michelle Elizabeth Matzko, Sama Adnan, David McNeel, Julie Ma, Sarah A Gilmore, Spyridoula Vasileiou, Ann M Leen, Joshua A Hill, ...> ;Blood Advances. 2024 Apr 9
- Deficient Generation of Spike-Specific Long-Lived Plasma Cells in the Bone Marrow After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.Zahra R Tehrani, Parham Habibzadeh, Robin Flinko, Hegang Chen, Abdolrahim Abbasi, Jean A Yared, Stanca M Ciupe, George K Lewis, Mohammad M Sajadi> ;The Journal of Infectious Diseases. 2024 Feb 14
- Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.Kline, K., Luetkens, T., Koka, R., Kallen, M., Chen, W., Ahmad, H., Omili, D., Iraguha, T., Gebru, E., Fan, X., Miller, A., Dishanthan, N., Baker, J., Dietze, K., Hank...> ;Cancer Immunology, Immunotherapy. 2024 Feb 13
- Join now to see all
Abstracts/Posters
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierJean A. Yared, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Jean A. Yared, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Other Languages
- French, Arabic
Hospital Affiliations
University of Maryland Medical CenterBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
